1. Home
  2. SXTC vs INM Comparison

SXTC vs INM Comparison

Compare SXTC & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China SXT Pharmaceuticals Inc.

SXTC

China SXT Pharmaceuticals Inc.

N/A

Current Price

$1.44

Market Cap

1.8M

Sector

Health Care

ML Signal

N/A

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$1.58

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTC
INM
Founded
2005
1981
Country
China
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
2.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SXTC
INM
Price
$1.44
$1.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.1K
3.0M
Earning Date
08-19-2019
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,942,633.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.50
52 Week Low
$0.03
$0.58
52 Week High
$6.98
$3.34

Technical Indicators

Market Signals
Indicator
SXTC
INM
Relative Strength Index (RSI) 38.02 69.62
Support Level $1.37 $1.56
Resistance Level $1.51 $1.95
Average True Range (ATR) 0.12 0.17
MACD 0.01 0.00
Stochastic Oscillator 15.89 67.94

Price Performance

Historical Comparison
SXTC
INM

About SXTC China SXT Pharmaceuticals Inc.

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: